Dr. Kinneret Savitsky
Dr. Savitsky served as CEO of BioLineRx from 2010 to 2016, and General Manager of BioLine Innovations Jerusalem at from 2004 to 2009. She previously served as VP, Biology, Research and Development at Compugen. Dr. Savitsky gained her Ph.D. at Tel Aviv University, a B.Sc. in Biology from the Hebrew University of Jerusalem and a Masters degree in Human Genetics from Tel Aviv University.
Dr. Tamar Raz
CEO of Hadasit, the Technology Transfer Company of Hadassah Medical Organization (HMO) in Jerusalem, Israel. In previous position, Dr. Raz served as VP Marketing and Strategy of Ramot, the Technology Transfer Company of Tel Aviv University. Prior to joining Ramot in 2004, she directed the establishment of Allergene, an Israeli start-up company that was founded as an incubator project, and served as its CEO.
Mr. Thomas Eldered
Co-owner and CEO of Recipharm AB, a Swedish company with a turnover of more than $400M, employing over 1,800 people across a number of sites in Europe. He has held this position since 2008. Prior to Recipharm he was Vice President of Recip AB from 1995 to 2007 and Factory Manager at Pharmacia from 1990 to 1995. He has a M.Sc. in Industrial and Management Engineering from the Linköping Institute of Technology.
Dr. Carl-Johan Spak
SVP Strategic Investments & Projects in Recipharm. He has been with Recipharm AB since 2009. Prior to his appointment at Recipharm he was Meda AB’s Director for the Nordic Region, from 2007 to 2008, CEO for Recip AB and Recip Läkemedel AB from 2005 to 2007, and part of the Executive Management Team for Recip AB from 1995 to 2005. Dr. Spak graduated with a Dentist degree 1980 and received his Ph.D 1984 from Karolinska Institutet.
Mr. Sangwoo Lee
Executive Director at Korea Investment Partners Co. (KIPC). He is responsible for global expansion and activities at KIPC and manages a diverse investment portfolio from Bio-Healthcare companies to IT companies. Mr. Lee received his B.S and M.S in Control and Instrumental Engineering from Seoul National University and has 18 years of experience in industry leaders such as Samsung and Dasan, as well as in successful venture startups where he served as CTO.
Mr. Michel Habib
Founder of Matar Capital Advisors. From 2007-2015 he was Managing General Partner of Agate Medical Investments LP, and is currently Managing General Partner of Agate-MaC fund. Previously he served as Elron Electronic Industries’ BD Director, established the investment banking activity of ING Barings in Israel, and served as VP Investment Banking at Cukierman & Co. He holds a BsC in Aeronautical Engineering from the Technion.
Mr. Jae Joon Kim (Observer)
Director of the Venture Investment Division of Mirae Asset Venture Investments. Mr. Kim successfully listed over 15 companies on the NASDAQ, KOSDAQ and KONEX, and manages a portfolio of more than 30 biopharmaceutical and diagnostics companies. Prior to Mirae Asset, Mr. Kim was a research associate at the Korean biotech Macrogen from 2002 to 2006. He holds a Master’s from the Graduate School of Medicine, Korea University.
Dr. Bernhard Kirschbaum (Consultant)
Executive VP, Global Research & Early Development at Merck Serono until the end of 2013. Dr. Kirschbaum has over 25 years of experience in pharmaceutical research and drug development and held leadership positions at multiple pharma giants such as Aventis, Sanofi and Merck Serono. He brings strong expertise in drug development in a broad range of disease areas including oncology, immuno-oncology, immunology, and CNS.